Questcor Reports Fourth Quarter and Full Year 2012 Results - Net Sales, EPS and Cash Flow from Operations Increase Significantly Over Prior Year Period - - Continues to Expand R&D Efforts - - Increases Quarterly Dividend 25% to $0.25 per share - PR Newswire ANAHEIM, Calif., Feb. 26, 2013 ANAHEIM, Calif., Feb. 26, 2013 /PRNewswire/ --Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) today reported financial results for the fourth quarter and full year ended December 31, 2012. Three Months Ended Three Months Ended Percentage Change 12/31/12 12/31/11 Net Sales $160.5 Million $75.5 Million 113% GAAP Diluted EPS $1.03 $0.48 115% Non-GAAP Diluted $1.09 $0.47 132% EPS Year Ended 12/31/12 Year Ended 12/31/11 Percentage Change Net Sales $509.3 Million $218.2 Million 133% GAAP Diluted EPS $3.14 $1.21 160% Non-GAAP Diluted EPS $3.33 $1.27 162% Net sales for the fourth quarter of 2012 were $160.5 million, compared to $75.5 million for the same period in 2011. Net sales increased primarily due to expanded prescribing of H.P. Acthar^® Gel (repository corticotropin injection) by nephrologists in the treatment of nephrotic syndrome, as well as continued prescribing by neurologists in the treatment of MS relapses and infantile spasms. Net sales also benefitted from the initiation of commercial activities focused on the use of Acthar by rheumatologists in the treatment of on-label rheumatology-related conditions. GAAP earnings for the fourth quarter of 2012 were $1.03 per diluted common share, compared to $0.48 per diluted common share for last year's comparable quarter.Non-GAAP earnings for the quarter ended December 31, 2012 were $1.09 per diluted common share and exclude non-cash share-based compensation expense and depreciation and amortization expense. Non-GAAP earnings for the year ago quarter were $0.47 per diluted common share. Basic common share count decreased over 5 million shares from the fourth quarter of 2011 to the fourth quarter of 2012. Questcor shipped 6,330 vials of Acthar during the fourth quarter 2012, up 88 percent compared to 3,360 vials in the year ago quarter.For the full year of 2012, Questcor shipped 20,741vials of Acthar, up 94 percent compared to 10,710 vials in 2011. Quarterly vial shipments are subject to significant variation due to the size and timing of individual orders received from Questcor's distributor.The timing of when these orders are received and filled can significantly affect net sales and net income in any particular quarter. The fourth quarter and full year results do not reflect Questcor's acquisition of BioVectra or the change, to be applied on a prospective basis, in the Medicaid rebate percentage for Acthar, both of which occurred in the first quarter of 2013. "Net sales, net income and cash flow from operations grew sharply in the fourth quarter compared to the prior-year period," said Don M. Bailey, President and CEO of Questcor. "Additionally, we more than doubled our investment in R&D in 2012 compared to 2011 as we continue to build the body of evidence regarding the unique properties of Acthar and how it may benefit an increasing number of patients who do not respond to other therapies." "Acthar is most commonly prescribed by physicians as an appropriate treatment alternative for patients with certain auto-immune conditions in whom first-line therapies have not provided the intended treatment outcome and an additional FDA-approved treatment alternative is needed," commented Steve Cartt, Chief Operating Officer of Questcor. "For such patients, insurance coverage for Acthar continues to remain favorable. Continued expanded use in nephrotic syndrome, MS and strong growth in our newly commercialized rheumatology indications, mainly dermatomyositis and polymyositis, contributed to the year-over-year net sales increase in the fourth quarter. While Acthar net sales in MS posted greater than 40% year-over-year growth, MS prescriptions softened by approximately 8% from the third quarter, after almost five years of sequential quarterly growth, and nephrotic syndrome became the largest contributor to net sales. At the same time, based on early, encouraging results from our pilot rheumatology commercial effort, we have just completed our rheumatology sales force expansion from 12 to 55 representatives." "We continue to invest in the future of both Acthar and our overall business capabilities," continued Mr. Bailey. "In addition to the rapid expansion of our R&D investment, we have also substantially expanded our sales force, our reimbursement and compliance teams, and our manufacturing capabilities. The recent acquisition of BioVectra, which gives us much greater control of our supply chain, deepens our manufacturing capabilities and scientific expertise, while also expanding and diversifying our business. The appointment of Michael Aldridge to lead our strategic development function was another important step as we look to broaden our capabilities and further diversify our business, while maintaining our focus on the potential of Acthar to help many more patients than it does today. We continue to balance our investments in the business with a disciplined program of returning capital to shareholders, as demonstrated by additional share repurchases and the institution of a regular quarterly dividend." Full Year Financial Results Net sales for the full year of 2012 were $509.3 million, compared to $218.2 million in the full year of 2011. Cash flow from operations for the full year of 2012 was $219.0 million, compared to $85.6 million for the full year of 2011. GAAP earnings per share for the full year of 2012 were $3.14 per diluted common share, compared with $1.21 per diluted common share for the comparable period of 2011. Non-GAAP earnings per share for the full year ended December 31, 2012 were $3.33 per diluted common share, excluding non-cash share-based compensation expense, depreciation and amortization expense, and impairment of intangibles. Non-GAAP earnings for the comparable period of 2011 were $1.27 per diluted common share. Research and Development Programs Questcor's continued strong financial performance has enabled the company to increase investment in research programs to further clarify the potential immune-modulating properties of Acthar and identify Acthar mechanisms of action applicable to other inflammatory and auto-immune diseases with high unmet need. Questcor currently has approximately 35 company-sponsored clinical and pre-clinical research projects underway. Key company-sponsored clinical programs are in process in the following disease states: oLupus: Enrollment is underway in a company-sponsored multi-site Phase 4 clinical trial to evaluate the efficacy and safety of daily Acthar administration over a 6-month period in patients with persistently active lupus. oIdiopathic Membranous Nephropathy: Enrollment continues in a company-sponsored Phase 4 trial in idiopathic membranous nephropathy. Patients enrolled in this study are refractory, or non-responsive, to current standard therapies or have relapsed after partial remission on current standard therapies. oDiabetic Nephropathy: Enrollment continues in a company-sponsored Phase 2 trial to evaluate the efficacy and safety of Acthar in patients with diabetic nephropathy, one of the most common causes of end-stage renal disease in the United States. oAmyotrophic Lateral Sclerosis (ALS): Questcor is in discussions with the U.S. Food and Drug Administration (FDA) to commence clinical trials of Acthar for the treatment of amyotrophic lateral sclerosis (ALS), often referred to as Lou Gehrig's disease. ALS is a life-threatening, progressive neurodegenerative disease that affects nerve cells in the brain and the spinal cord. The company expects to file an Investigational New Drug application (IND) and initiate a proof-of-concept trial of Acthar in ALS in the first half of 2013. In addition, Questcor provides grant funding to a wide range of independent research projects, which include the evaluation of Acthar in nephrotic syndrome due to focal segmental glomerulosclerosis (FSGS), nephrotic syndrome due to lupus nephritis, lupus flares, intractable chronic migraine, multiple sclerosis, prevention of infantile spasms in at-risk patients, and others. The company is currently funding more than 30 such independent research programs, including both preclinical and clinical studies. Questcor continues to receive case reports and inquiries from physicians indicating that Acthar may be able to benefit patients whose serious illnesses are not effectively treated with other medications, but for which Questcor does not currently have an active sales force providing information to specialists who treat these illnesses. As it has over the last several years, Questcor continues to follow up on these reports and inquiries in order to ascertain whether the Company should fund research regarding the potential utility of Acthar in treating these serious illnesses. Past reports and inquiries have led to the company's current work in MS and rheumatology. More recent reports and inquiries may lead Questcor to expand its internal research and development, including clinical trials, and other activities within current on-label or potential new indications. Share Repurchase Program and Cash Dividend During the fourth quarter of 2012, Questcor used $18.6 million in cash to repurchase 747,207 shares of its common stock in open market transactions, at an average price of $24.93 per common share. Since the beginning of 2008, the company has repurchased a total of 22.2 million shares of its common stock for $340.3 million through December 31, 2012, at an average price of $15.36 per share. As of December 31, 2012, there are approximately 6.3 million shares authorized remaining under the stock repurchase plan. Shares outstanding were 58.5 million at December 31, 2012 and 63.6 million at December 31, 2011. The company today announced that its Board of Directors has declared a quarterly cash dividend of$0.25per share to all shareholders of record at the close of business onApril 22, 2013. The quarterly cash dividend was increased from $0.20 per share, or 25% over the previous quarterly dividend. The dividend is scheduled to be paid on or aboutApril 30, 2013. Questcor currently intends to pay regular quarterly cash dividends for the foreseeable future. 2012 Corporate Highlights oDuring 2012, approximately 7,000 patients received new prescriptions for Acthar. oDuring 2012, additional academic papers were published providing incremental information regarding Acthar and its potential immuno-modulating properties and mechanisms of action. oDuring 2012, Questcor initiated two multi-center clinical trials, continued enrollment in a third, and initiated discussions with the FDA for a fourth trial. oDuring the second quarter of 2012, the company completed the expansion of its Nephrology sales force to 58 from 28 representatives. oIn the third quarter of 2012, the company completed the expansion of its neurology sales force to 107 from 77 representatives. oIn the third quarter of 2012, Questcor initiated commercial efforts for Acthar in the treatment of rheumatology-related indications already included on the FDA-approved package insert for Acthar. Acthar is indicated for multiple FDA-approved rheumatology-related conditions, including its use as adjunctive therapy in psoriatic arthritis, rheumatoid arthritis, juvenile rheumatoid arthritis, and ankylosing spondylitis. Acthar is also approved by the FDA as acute or maintenance therapy in selected cases of systemic lupus erythematosus and systemic dermatomyositis (polymyositis). oIn the fourth quarter of 2012, the company initiated the expansion of its rheumatology sales force to 55 from 12 rheumatology representatives. oQuestcor also continued to demonstrate its commitment to returning capital to shareholders, by expanding its common share repurchase program authorization by an additional 5 million shares and adopting a policy to pay a regular quarterly dividend in September 2012. The company repurchased 6.8 million shares in 2012. Following the end of the fourth quarter of 2012: oOn January 18, 2013, Questcor acquired BioVectra Inc. for an upfront payment of $50.8 million. BioVectra has been Questcor's manufacturing partner for the active pharmaceutical ingredient (API) in Acthar for nearly a decade. The acquisition further secures the manufacturing process trade secrets surrounding Acthar. oDuring the first quarter of 2013, the Medicaid rebate amount for Acthar was reset to the standard basic rebate. oOn January 28, 2013, Questcor strengthened its management team with the appointment of Michael Aldridge to the new position of Senior Vice President, Corporate Strategic Development. Mr. Aldridge's primary responsibilities will be the identification and development of partnership and acquisition opportunities to leverage Questcor's business model. Over time, such initiatives may include development programs or products complementary to Acthar and the evaluation of potential expansion into ex-US markets. Acthar Label Information The product label for Acthar includes 19 FDA-approved indications. Substantially all of the Company's net sales currently result from Acthar prescriptions for the following on-label indications of: oNephrotic Syndrome (NS): "to induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus." NS can result from several underlying conditions, and prescribing physicians indicate that Acthar is most commonly being prescribed for patients who suffer from NS due to idiopathic membranous nephropathy, focal segmental glomerulosclerosis (FSGS), IgA nephropathy, minimal change disease and lupus nephritis. oMultiple Sclerosis (MS): "for the treatment of acute exacerbations of multiple sclerosis in adults. Clinical controlled trials have shown H.P. Acthar Gel to be effective in speeding the resolution of acute exacerbations of multiple sclerosis. However, there is no evidence that it affects the ultimate outcome or natural history of the disease." When Acthar is used, it is typically prescribed as second line treatment for patients with MS exacerbations. oInfantile Spasms (IS): "as monotherapy for the treatment of infantile spasms in infants and children under 2 years of age." oCollagen Diseases: "during an exacerbation or as maintenance therapy in selected cases of: systemic lupus erythematosus, systemic dermatomyositis (polymyositis)." oRheumatic Disorders: "as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis, Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy), Ankylosing spondylitis." Non-GAAP Financial Measures The company believes it is important to share non-GAAP financial metrics with shareholders as these metrics may better represent the ongoing economics of the business and reflect how we manage the business. Accordingly, management believes investors' understanding of the company's financial performance is enhanced as a result of the disclosure of these non-GAAP financial metrics. Non-GAAP net income should not be viewed in isolation, or as a substitute for, or as superior to, reported GAAP net income. The reconciliation between GAAP and Non-GAAP net income is provided with the financial tables included with this release. Conference Call and Webcast and Investor Communications The company will host a conference call and slide presentation via webcast today, February 26, 2013, at 4:30 p.m. ET/ 1:30 p.m. PT. The call can be accessed three ways: oBy webcast: At Questcor's investor relations website, http://ir.questcor.com/. oBy telephone: For both "listen-only" participants and those participants who wish to take part in the question-and-answer portion of the call, the telephone dial-in number in the U.S. is (877) 354-0215. For participants outside the U.S., the dial-in number is (253) 237-1173. oBy audio replay: A replay of the conference call will be available for seven business days following conclusion of the live call.The dial-in number for U.S. participants is (855) 859-2056. For participants outside the U.S., the replay dial-in number is (404) 537-3406. The replay access code for all callers is 95427085. About Questcor Questcor Pharmaceuticals, Inc. is a biopharmaceutical company focused on the treatment of patients with serious, difficult-to-treat autoimmune and inflammatory disorders. Questcor's primary product is H.P. Acthar^® Gel (repository corticotropin injection), an injectable drug that is approved by the FDA for the treatment of 19 indications. Of these 19 indications, Questcor currently generates substantially all of its net sales from the following on-label indications: the treatment of proteinuria in the nephrotic syndrome of the idiopathic type, or NS, the treatment of acute exacerbations of multiple sclerosis, or MS, in adults, the treatment of infantile spasms, or IS, in infants and children under two years of age, and the treatment of certain rheumatology related conditions, including the treatment of the rare and closely related neuromuscular disorders dermatomyositis and polymyositis. With respect to nephrotic syndrome, the FDA has approved Acthar to "induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus. Questcor is also exploring the possibility of developing markets for other on-label indications and the possibility of pursuing FDA approval of additional indications not currently on the Acthar label where there is high unmet medical need. For more information about Questcor, please visit www.questcor.com. Note: Except for the historical information contained herein, this press release contains forward-looking statements that have been made pursuant to the Private Securities Litigation Reform Act of 1995. These statements relate to future events or our future financial performance. In some cases, you can identify forward-looking statements by terminology such as "believes," "continue," "could," "estimates," "expects," "growth," "may," "plans," "potential," "remain," "should," "substantial" or "will" or the negative of such terms and other comparable terminology. These statements are only predictions. Actual events or results may differ materially. Factors that could cause or contribute to such differences include, but are not limited to, the following: oOur reliance on Acthar for substantially all of our net sales and profits; oReductions in vials used per prescription resulting from changes in treatment regimens by physicians or patient compliance with physician recommendations; oOur ability to receive high reimbursement levels from third party payers; oThe complex nature of our manufacturing process and the potential for supply disruptions or other business disruptions; oThe lack of patent protection for Acthar; and the possible FDA approval and market introduction of competitive products; oOur ability to continue to generate revenue from sales of Acthar to treat on-label indications associated with NS, MS, IS or rheumatology-related conditions, and our ability to develop other therapeutic uses for Acthar; oResearch and development risks, including risks associated with Questcor's work in the area of NS and Lupus, our reliance on third-parties to conduct research and development, and the ability of research and development to generate successful results; oThe results of any pending or future litigation, investigations or claims, including with respect to the investigation by the United States Attorney's Office for the Eastern District of Pennsylvania regarding the company's promotional practices and litigation brought by certain shareholders arising from the federal securities laws, currently pending in the United States District Court for the Central District of California; oOur ability to comply with federal and state regulations, including regulations relating to pharmaceutical sales and marketing practices; oRegulatory changes or other policy actions by governmental authorities and other third parties in connection with U.S. health care reform or efforts to reduce federal and state government deficits; oAn increase in the proportion of our Acthar unit sales comprised of Medicaid-eligible patients and government entities; oOur ability to estimate reserves required for Acthar used by government entities and Medicaid-eligible patients and the impact that unforeseen invoicing of historical Medicaid prescriptions may have upon our results; oOur ability to effectively manage our growth, including the expansion of our sales forces, and our reliance on key personnel; oOur ability to integrate the BioVectra business with our business and to manage, and grow, a contract manufacturing business; oOur ability to comply with foreign regulations related to the operation of BioVectra's business; oThe impact to our business caused by economic conditions; oOur ability to protect our proprietary rights; oThe risk of product liability lawsuits; oUnforeseen business interruptions and security breaches; oVolatility in Questcor's monthly and quarterly Acthar shipments, estimated channel inventory, and end-user demand, as well as volatility in our stock price; oOur ability and willingness to continue to pay our quarterly dividend or make future increases in our quarterly dividend; and oOther risks discussed in Questcor's annual report on Form 10-K for the year ended December 31, 2011 as filed with the Securities and Exchange Commission, or SEC, on February 22, 2012, and other documents filed with the SEC. The risk factors and other information contained in these documents should be considered in evaluating Questcor's prospects and future financial performance. Questcor undertakes no obligation to publicly release the result of any revisions to these forward-looking statements, which may be made to reflect events or circumstances after the date of this release. For more information, please visit www.questcor.com or www.acthar.com. Questcor Pharmaceuticals, Inc. Consolidated Statements of Income (In thousands, except per share amounts) Three Months Ended Twelve Months Ended December 31, December 31, 2012 2011 2012 2011 Net sales $ 160,532 $ 75,535 $ 509,292 $ 218,169 Cost of sales (exclusive of amortization of 9,156 4,013 28,555 12,459 purchased technology) Gross profit 151,376 71,522 480,737 205,710 Operating expenses: Selling and marketing 33,051 16,998 114,139 56,728 General and administrative 11,175 5,766 33,596 17,743 Research and development 12,122 5,730 34,269 16,778 Depreciation and 268 292 1,219 1,044 amortization Impairment of goodwill and — — 987 299 intangibles Total operating expenses 56,616 28,786 184,210 92,592 Income from operations 94,760 42,736 296,527 113,118 Other income: Interest and other income, 167 145 703 627 net Total other income 167 145 703 627 Income before income taxes 94,927 42,881 297,230 113,745 Income tax expense 32,987 11,240 99,555 34,154 Net income $ 61,940 $ 31,641 $ 197,675 $ 79,591 Net income per share applicable to common shareholders: Basic $ 1.07 $ 0.50 $ $ 3.28 1.27 Diluted $ 1.03 $ 0.48 $ $ 3.14 1.21 Shares used in computing net income per share applicable to common shareholders: Basic 58,009 63,236 60,243 62,498 Diluted 60,266 66,565 63,045 66,010 Dividends declared per $ 0.20 $ — $ $ common shareholder 0.40 — Reconciliation of Non-GAAP Adjusted Financial Adjusted net income $ 65,705 $ 31,584 $ 209,644 $ 83,956 Share-based compensation (3,590) (1,416) (10,502) (5,128) expense (1) Depreciation and (175) (216) (811) (731) amortization expense (2) Impairment of goodwill and 0 - (656) (209) intangibles (3) Tax adjustments (4) 0 1,689 0 1,703 Net income - GAAP $ 61,940 $ 31,641 $ 197,675 $ 79,591 Adjusted net income per $ $ 0.50 $ $ share - basic 1.13 3.48 1.34 Share-based compensation (0.06) (0.02) (0.17) (0.08) expense (1) Depreciation and (0.00) (0.00) (0.01) (0.01) amortization expense (2) Impairment of goodwill and 0.00 0.00 (0.01) 0.00 intangibles (3) Tax adjustments (4) 0.00 0.03 0.00 0.03 Net income per share - $ $ 0.50 $ $ basic 1.07 3.28 1.27 Adjusted net income per $ $ 0.47 $ $ share - diluted 1.09 3.33 1.27 Share-based compensation (0.06) (0.02) (0.17) (0.08) expense (1) Depreciation and (0.00) (0.00) (0.01) (0.01) amortization expense (2) Impairment of goodwill and 0.00 0.00 (0.01) 0.00 intangibles (3) Tax adjustments (4) 0.00 0.03 0.00 0.03 Net income per share - $ $ 0.48 $ $ diluted 1.03 3.14 1.21 Net income per share – basic and diluted may not foot due to rounding. Use of Non-GAAP Financial Measures Our "non-GAAP adjusted net income" excludes the following items from GAAP net income: 1. Share-based compensation expense. 2. Depreciation and amortization expense 3. Impairment of purchased technology in 2012 related to the acquisition of Doral and impairment of goodwill related to the write-off of goodwill associated with an acquisition completed in 1999, written off in 2011. 4. Tax adjustments include: (1) the valuation allowance we established in the fourth quarter of 2010 relating to our single sales factor apportionment election which was made in 2011 for California; and (2) the recording of a one-time tax credit in 2011 for the orphan drug designation. Questcor Pharmaceuticals, Inc. Consolidated Balance Sheets (In thousands, except per share amounts) December 31, December 31, 2012 2011 ASSETS Current assets: Cash and cash equivalents $ 80,608 $ 88,469 Short-term investments 74,705 121,680 Total cash, cash equivalents and short-term 155,313 210,149 investments Accounts receivable, net of allowance for doubtful accounts of $0 at both December31, 2012 and 2011, 61,417 27,801 respectively Inventories, net 9,909 5,226 Prepaid income taxes — 6,940 Prepaid expenses and other current assets 4,900 3,391 Deferred tax assets 5,737 12,093 Total current assets 237,276 265,600 Property and equipment, net 2,073 1,970 Purchased technology, net 1,493 2,778 Goodwill — — Deposits and other assets 70 56 Deferred tax assets 11,519 5,404 Total assets $252,431 $275,808 LIABILITIES AND SHAREHOLDERS' EQUITY Current liabilities: Accounts payable $ 13,069 $ 5,503 Accrued compensation 21,300 11,590 Sales-related reserves 37,376 34,119 Income taxes payable 7,360 — Other accrued liabilities 11,294 4,509 Total current liabilities 90,399 55,721 Lease termination, deferred rent and other 203 261 non-current liabilities Total liabilities 90,602 55,982 Shareholders' equity: Preferred stock, no par value, 5,334,285shares — — authorized; none outstanding Common stock, no par value, 105,000,000shares authorized; 58,544,206 and 63,645,781shares issued 15,938 94,976 and outstanding at December31, 2012 and 2011, respectively Retained earnings 145,851 124,886 Accumulated other comprehensive income (loss) 40 (36) Total shareholders' equity 161,829 219,826 Total liabilities and shareholders' equity $252,431 $275,808 Questcor Pharmaceuticals, Inc. Consolidated Statements of Cash Flows (In thousands) Years Ended December31, 2012 2011 2010 (In thousands) Cash Flows From Operating Activities Net income $197,675 $ 79,591 $ 35,071 Adjustments to reconcile net income to net cash provided by operating activities: Share-based compensation expense 15,792 7,326 3,739 Deferred income taxes 241 (4,896) (1,029) Amortization of investments 1,330 1,250 678 Depreciation and amortization 1,219 1,044 546 Impairment of goodwill and intangibles 987 299 — Loss on disposal of property and equipment 72 11 — Changes in operating assets and liabilities: Accounts receivable (33,616) (16,673) 3,705 Inventories (4,683) (1,500) (348) Prepaid income taxes 6,940 (3,408) (3,532) Income taxes payable 7,360 — — Prepaid expenses and other current assets (1,509) (1,527) (702) Accounts payable 7,566 1,634 (9,052) Accrued compensation 9,710 7,432 2,018 Sales-related reserves 3,257 12,608 6,589 Other accrued liabilities 6,780 2,526 (255) Other non-current liabilities (84) (118) (871) Net cash provided by operating activities 219,037 85,599 36,557 Cash Flows From Investing Activities Purchase of short-term investments (145,384) (162,301) (106,647) Proceeds from the sale and maturities of 191,105 112,636 62,560 short-term investments Purchase of property, equipment and (1,065) (1,823) (713) leasehold improvements Changes in deposits and other assets (14) 9 645 Net cash provided by /(used in) investing 44,642 (51,479) (44,155) activities Cash Flows From Financing Activities Income tax benefit realized from 7,488 17,712 1,335 share-based compensation plans Issuance of common stock, net 6,335 6,582 1,942 Dividends paid (23,533) — — Repurchase of common stock (261,830) (11,453) — Net cash (used in) / provided by financing (271,540) 12,841 3,277 activities (Decrease) / increase in cash and cash (7,861) 46,961 (4,321) equivalents Cash and cash equivalents at beginning of 88,469 41,508 45,829 year Cash and cash equivalents at end of year $ 80,608 $ 88,469 $ 41,508 Supplemental Disclosures of Cash Flow Information: Cash paid for interest $ 23 $ 16 $ 7 Cash paid for income taxes $ 77,556 $ 25,278 $ 23,185 Supplemental disclosure of non-cash investing and financing activities: Capital lease obligation $ 31 $ 34 $ — SOURCE Questcor Pharmaceuticals, Inc. Website: http://www.questcor.com Contact: EVC Group, Gregory Gin/Patty Eisenhaur, +1-646-445-4801/+1-951-316-0577, or Doug Sherk, +1-415-568-4887, or Janine McCargo, +1-646-688-0425
Questcor Reports Fourth Quarter and Full Year 2012 Results
Press spacebar to pause and continue. Press esc to stop.